Omega 3 and 6 Fatty Acids

Omega-3 and -6 Fatty Acids

Test Code 

91001

CPT Code(s)

82542

Patient Preparation

Overnight fasting is required. 

Methodology

Liquid Chromatography/Tandem Mass Spectrometry (LC/MS/MS)

Reference Range(s)

 

Omega-3 (EPA+DHA) Index 1.4-4.9 %
Risk:  
Index <2.2: High
Index 2.2-3.2: Moderate
Index >3.2: Low
Omega-6/Omega-3 Ratio 5.7-21.3
EPA/Arachidonic Acid Ratio ≤0.2
Arachidonic Acid 5.2-12.9%
EPA 0.2-1.5 %
DHA 1.2-3.9 %

 

Clinical Significance

1. Baseline and monitoring of individuals with known CVD (acute and chronic) to determine Rx and compliance.
2. Identify patients with known CVD risk with low omega-3 levels who may be candidates for supplementation/therapy.
3. Monitor patients on omega-3 supplementation/therapy to determine efficacy of treatment.
4. Potential role in risk reduction for non-CVD outcomes-aged related macular degeneration, RA, cancer, etc. (early data).

Alternative Name(s)

Polyunsaturated Fatty Acids (PUFAs),EPA,Omega-3 Index,Omega-6/omega-3 Ratio,Phospholipid Omega-3 Fatty Acid,Arachidonic Acid/EPA Ratio,DHA,Arachidonic Acid (AA),Phospholipid Omega-6 Fatty Acid

Expect Results in 3 to 4 business days. Fast for 10 hours prior to blood draw. While fasting do continue drinking water and taking any prescribed medication.  If you are pregnant or diabetic, do not fast without consulting your physician.

Please be advised, that our services are strictly self pay and are not eligible for submission as a claim to your health insurance provider. However, you can submit the receipt for reimbursement to many Flexible Spending and Health Savings Accounts for reimbursement.

Sample of Omega-3 and -6 Fatty Acids test

Omega-3 and -6 Fatty Acids

Test Code 

91001

CPT Code(s)

82542

Patient Preparation

Overnight fasting is required. 

Methodology

Liquid Chromatography/Tandem Mass Spectrometry (LC/MS/MS)

Reference Range(s)

 

Omega-3 (EPA+DHA) Index 1.4-4.9 %
Risk:  
Index <2.2: High
Index 2.2-3.2: Moderate
Index >3.2: Low
Omega-6/Omega-3 Ratio 5.7-21.3
EPA/Arachidonic Acid Ratio ≤0.2
Arachidonic Acid 5.2-12.9%
EPA 0.2-1.5 %
DHA 1.2-3.9 %

 

Clinical Significance

1. Baseline and monitoring of individuals with known CVD (acute and chronic) to determine Rx and compliance.
2. Identify patients with known CVD risk with low omega-3 levels who may be candidates for supplementation/therapy.
3. Monitor patients on omega-3 supplementation/therapy to determine efficacy of treatment.
4. Potential role in risk reduction for non-CVD outcomes-aged related macular degeneration, RA, cancer, etc. (early data).

Alternative Name(s)

Polyunsaturated Fatty Acids (PUFAs),EPA,Omega-3 Index,Omega-6/omega-3 Ratio,Phospholipid Omega-3 Fatty Acid,Arachidonic Acid/EPA Ratio,DHA,Arachidonic Acid (AA),Phospholipid Omega-6 Fatty Acid

Expect Results in 3 to 4 business days. Fast for 10 hours prior to blood draw. While fasting do continue drinking water and taking any prescribed medication.  If you are pregnant or diabetic, do not fast without consulting your physician.

Please enter details below to search the lab nearest to you.